SOL-GEL TECHNOLOGIES LTD
SOL-GEL Technologies Ltd (ticker: SLGL) is a small-cap materials company best known for developing and applying sol‑gel based surface treatments and advanced functional coatings. With a market capitalisation around $111.43M, it sits in a growth‑stage segment where revenues and margins can move quickly depending on product adoption, contracts and R&D outcomes. Investors should note the company’s focus on proprietary processing and specialised end markets — this can create opportunity if technology wins customers, but it also brings execution and commercialisation risks. Liquidity and price volatility tend to be higher for smaller listed companies. This summary is for general, educational purposes only and is not personalised investment advice. Prospective investors should review the company’s financial reports, recent regulatory filings and analyst commentary, and consider their own risk tolerance and investment horizon or seek regulated financial advice before deciding if SLGL is suitable for them.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying SOL-GEL Technologies' stock with a target price of $50, indicating strong potential growth.
Financial Health
SOL-GEL is generating steady revenue and cash flow, but its overall financial position shows mixed signals.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring SLGL
Injectable Drug Innovation Opportunities 2025
The FDA's approval of an at-home injectable version of Eisai and Biogen's Alzheimer's drug, Leqembi, simplifies treatment for patients and caregivers. This development highlights a growing trend toward patient-centric care, creating investment opportunities in companies that specialize in innovative drug delivery systems and at-home therapeutic technologies.
Published: August 31, 2025
Explore BasketOral Obesity Treatments: Beyond The Needle
Following successful Phase 3 trials for its oral weight-loss drug, orforglipron, Eli Lilly is positioned to enter the lucrative obesity treatment market. This development creates a new investment theme focused on pharmaceutical companies developing patient-friendly, oral alternatives to injectable GLP-1 therapies.
Published: August 27, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Commercial traction watch
Monitor contract wins and customer pilots as signs of commercial adoption; remember small‑cap announcements can move the share price significantly and outcomes vary.
Technology edge
Proprietary sol‑gel processes can offer differentiation in coatings and functional surfaces, but continued R&D and scale‑up are needed to turn innovation into reliable revenue.
End‑market exposure
Performance depends on demand in industries like industrial manufacturing and specialty applications; macro cycles and supply chains can influence results.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
